Skip to content
Screener

Lineage Cell Therapeutics LCTX Q4 2025 Annual earnings

Reported March 5, 2026 · After market close

Revenue$6.6MBeat by $4.6M
EPS$0.00Beat by $0.05
Revenue estimate$2.0M
EPS estimate-$0.04

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$1.3M
EPS estimate-$0.03

FAQ

When did Lineage Cell Therapeutics report Q4 2025 earnings?
Lineage Cell Therapeutics (LCTX) reported Q4 2025 earnings on March 5, 2026 after market close.
What were Lineage Cell Therapeutics's Q4 2025 revenue and EPS?
Lineage Cell Therapeutics reported revenue of $6.6M and eps of $0.00 for Q4 2025.
Did Lineage Cell Therapeutics beat estimates in Q4 2025?
Revenue beat the consensus estimate of $2.0M by $4.6M. EPS beat the consensus estimate of $-0.04 by $0.05.
How did Lineage Cell Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 130.1% from $2.9M a year earlier.
Where can I find Lineage Cell Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-093948) and the 10-K periodic report (0001193125-26-093992) directly on SEC EDGAR. The filing index links above go to sec.gov.